TRON Seminar in Translational Oncology: Prof. Hans Lehrach

September 18, 2014

“Personalization of cancer therapy”

5PM in Mainz, Germany

Lecture Hall, Building 708, at University Medical Center Mainz
Langenbeckstr. 1
55131 Mainz

Prof. Lehrach

Hans Lehrach is Director and Scientific Member at the Max Planck Institute for Molecular Genetics, with a focus on genetics, genomics and systems biology.

His scientific achievements are numerous, among those are the early contribution to the cloning of collagen cDNA, early positional cloning work (Chorea Huntington gene etc.), key work on technologies such as protein microarrays, protein interactome analysis, yeast artificial chromosomes and RNAseq, as well as the involvement in several genome sequencing projects, such as the human, rat, and Schizosaccharomyces Pombe. During the last decade, a major focus of his work has been the development of a new, truly personalised medicine on the basis of ‘virtual patient’ models, based on a deep –omics analysis of the patient. He has received several awards such as the Ján Jessenius SAS Medal of Honour for outstanding achievements in medical sciences of the Slovak Academy of Sciences (2003) and the Karl Heinz Beckurts Award for achievements in genome research (2004).

Hans Lehrach has co-founded several biotechnology companies such as Sequana Therapeutics, GPC Biotech, Scienion, Prot@gen, PSF Biotech, Atlas Biolabs, Alacris Theranostics, as well as the Dahlem Centre for Genome Research and Medical Systems Biology gGmbH (DCGMS).

For additional information, please see: